Table 1. Percentages of antimicrobial drug resistance in selected bacterial species in wound infections, Ghana, 2014*.
| Drug | % Resistant |
|||||||
|---|---|---|---|---|---|---|---|---|
| Staphylococcus aureus, n = 31 | Enterococcus faecalis, n = 21 | Proteus mirabilis, n = 20 | Escherichia coli, n = 19 | Klebsiella pneumoniae, n = 13 | Enterobacter cloacae complex, n = 10 | Pseudomonas aeruginosa, n = 20 | Acinetobacter. baumannii complex, n = 8 | |
| PEN | 93.5 | |||||||
| AMP | 0 | 70.0 | 94.7 | 100 | 100 | |||
| OXA | 0 | |||||||
| SAM | 0 | 45.0 | 82.2 | 69.2 | 100 | |||
| TZP | 0 | 10.5 | 46.2 | 30.0 | 10.0 | |||
| CXM | 5.0 | 57.9 | 46.2 | 80.0 | ||||
| CTX | 5.0 | 47.4 | 46.2 | 40.0 | ||||
| CAZ | 5.0 | 47.4 | 46.2 | 40.0 | 5.0 | 37.5† | ||
| IPM | 0 | 0 | ||||||
| MEM | 0 | 0 | 0 | 0 | 5.0 | 0 | ||
| ERY | 3.2 | 100 | ||||||
| CLI | 3.2 | 100 | ||||||
| TET | 67.7 | 100 | ||||||
| GEN | 3.2 | 15.0 | 46.2 | 46.2 | 40.0 | 10.0 | 62.5 | |
| AMI | 0 | 0 | ||||||
| CIP | 20.0 | 46.2 | 46.2 | 30.0 | 15.0 | 37.5 | ||
| LVX | 0 | |||||||
| SXT | 32.3 | 100 | 75.0 | 69.2 | 69.2 | 50.0 | ||
| FOF | 0 | |||||||
| RIF | 0 | |||||||
| VAN | 0 | 0 | ||||||
*Antimicrobial susceptibility testing was performed with VITEK 2 (bioMérieux, Marcy-l'Étoile, France) according to the EUCAST breakpoint tables for interpretation of MICs, version 4.0, 2014 (7). Blank cells indicate no testing performed. AMI, amikacin; AMP, ampicillin; CAZ, ceftazidime; CIP, ciprofloxacin; CLI, clindamycin; CTX, cefotaxime; CXM, cefuroxime; ERY, erythromycin; FOF, fosfomycin; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; OXA, oxacillin; PEN, penicillin; RIF, rifampin; SAM, ampicillin/sulbactam; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; TZP, piperacillin/tazobactam; VAN, vancomycin. †The interpretation of the CAZ MIC for A. baumannii complex followed the recommendations of the Clinical and Laboratory Standards Institute performance standards for antimicrobial susceptibility testing (8).